Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

NeutroFlow Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples

Coordinator
Oncohost, Israel
Runs
1 May 2025 to 30 April 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
5 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101213660

What the project is doing

In the project's own words, from its summary on CORDIS.

The recent introduction of cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has revolutionised the treatment landscape for a broad range of cancer types. However, response to ICIs varies widely between patients, with the majority experiencing resistance to therapy. Moreover, the increasing use of these costly drugs coupled with management of ICI-related toxicities creates a substantial economic burden.

Current biomarker tests for determining eligibility for ICIs have limited predictive performance, and many require invasive tumour biopsies. Thus, novel (and preferentially non-invasive) biomarkers for predicting ICI clinical benefit are desperately needed for better guiding clinical decisions. The NeutroFlow project directly addresses this unmet need. We build on comprehensive academic research describing a flow cytometry assay for measuring a novel predictive biomarker in the blood – Ly6Ehi neutrophil – that accurately predicts therapeutic benefit from ICIs, outperforming the approved PD-L1 biomarker.

The NeutroFlow project aims to upgrade the research-level assay to an industry-level, point-of-care prototype test based on a kit comprised of an antibody panel for biomarker detection by standard flow cytometry (FC). Specifically, we will: (i) develop an FC assay according to clinical standards; (ii) develop and clinically validate a computational model that translates FC readout into a prediction of clinical benefit; (iii) evaluate analytical validity of the prototype across three medical centres (i.e., at the point-of-care); and (iv) prepare for future market introduction.

The future product represents a minimally-invasive, simple, rapid, cost-effective test performed using standard hospital equipment. As a pan-cancer blood test for accurately predicting ICI therapeutic benefit, the product will potentially expand the benefit of ICIs to more patients, improve quality of life, limit the risk of ICI-related toxicities and reduce economic burden.

Topics

Who is involved

OrganisationCityCountryRole
OncohostBinyaminaIsraelCoordinator
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
Fundacion Para La Gestion De La Investigacion En Salud De SevillaSevillaSpainThird party
Servicio Andaluz De SaludSevillaSpainParticipant
Istituto Europeo Di Oncologia SRLMilanoItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI